A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial”
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount imp...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kedhi, Elvin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: 625: Withdrawn - 2013, AHJ, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:188 ; year:2017 ; pages:11-17 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ahj.2017.02.018 |
|---|
| Katalog-ID: |
ELV030747783 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV030747783 | ||
| 003 | DE-627 | ||
| 005 | 20230623210010.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ahj.2017.02.018 |2 doi | |
| 028 | 5 | 2 | |a GBVA2017019000017.pica |
| 035 | |a (DE-627)ELV030747783 | ||
| 035 | |a (ELSEVIER)S0002-8703(17)30053-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 100 | 1 | |a Kedhi, Elvin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” |
| 264 | 1 | |c 2017 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. | ||
| 700 | 1 | |a Fabris, Enrico |4 oth | |
| 700 | 1 | |a van der Ent, Martin |4 oth | |
| 700 | 1 | |a Kennedy, Mark W. |4 oth | |
| 700 | 1 | |a Buszman, Pawel |4 oth | |
| 700 | 1 | |a von Birgelen, Clemens |4 oth | |
| 700 | 1 | |a Cook, Stéphane |4 oth | |
| 700 | 1 | |a Wedel, Hans |4 oth | |
| 700 | 1 | |a Zijlstra, Felix |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |t 625: Withdrawn |d 2013 |d AHJ |g Amsterdam [u.a.] |w (DE-627)ELV011791055 |
| 773 | 1 | 8 | |g volume:188 |g year:2017 |g pages:11-17 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ahj.2017.02.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 188 |j 2017 |h 11-17 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
e k ek |
|---|---|
| matchkey_str |
kedhielvinfabrisenricovanderentmartinken:2017----:popcieadmzdpnaetilfmnhess2otdaatpaeeteayfedueuigtnipattoiseeainycri |
| hierarchy_sort_str |
2017 |
| publishDate |
2017 |
| allfields |
10.1016/j.ahj.2017.02.018 doi GBVA2017019000017.pica (DE-627)ELV030747783 (ELSEVIER)S0002-8703(17)30053-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Kedhi, Elvin verfasserin aut A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. Fabris, Enrico oth van der Ent, Martin oth Kennedy, Mark W. oth Buszman, Pawel oth von Birgelen, Clemens oth Cook, Stéphane oth Wedel, Hans oth Zijlstra, Felix oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:188 year:2017 pages:11-17 extent:7 https://doi.org/10.1016/j.ahj.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 188 2017 11-17 7 045F 610 |
| spelling |
10.1016/j.ahj.2017.02.018 doi GBVA2017019000017.pica (DE-627)ELV030747783 (ELSEVIER)S0002-8703(17)30053-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Kedhi, Elvin verfasserin aut A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. Fabris, Enrico oth van der Ent, Martin oth Kennedy, Mark W. oth Buszman, Pawel oth von Birgelen, Clemens oth Cook, Stéphane oth Wedel, Hans oth Zijlstra, Felix oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:188 year:2017 pages:11-17 extent:7 https://doi.org/10.1016/j.ahj.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 188 2017 11-17 7 045F 610 |
| allfields_unstemmed |
10.1016/j.ahj.2017.02.018 doi GBVA2017019000017.pica (DE-627)ELV030747783 (ELSEVIER)S0002-8703(17)30053-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Kedhi, Elvin verfasserin aut A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. Fabris, Enrico oth van der Ent, Martin oth Kennedy, Mark W. oth Buszman, Pawel oth von Birgelen, Clemens oth Cook, Stéphane oth Wedel, Hans oth Zijlstra, Felix oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:188 year:2017 pages:11-17 extent:7 https://doi.org/10.1016/j.ahj.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 188 2017 11-17 7 045F 610 |
| allfieldsGer |
10.1016/j.ahj.2017.02.018 doi GBVA2017019000017.pica (DE-627)ELV030747783 (ELSEVIER)S0002-8703(17)30053-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Kedhi, Elvin verfasserin aut A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. Fabris, Enrico oth van der Ent, Martin oth Kennedy, Mark W. oth Buszman, Pawel oth von Birgelen, Clemens oth Cook, Stéphane oth Wedel, Hans oth Zijlstra, Felix oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:188 year:2017 pages:11-17 extent:7 https://doi.org/10.1016/j.ahj.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 188 2017 11-17 7 045F 610 |
| allfieldsSound |
10.1016/j.ahj.2017.02.018 doi GBVA2017019000017.pica (DE-627)ELV030747783 (ELSEVIER)S0002-8703(17)30053-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid Kedhi, Elvin verfasserin aut A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” 2017 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. Fabris, Enrico oth van der Ent, Martin oth Kennedy, Mark W. oth Buszman, Pawel oth von Birgelen, Clemens oth Cook, Stéphane oth Wedel, Hans oth Zijlstra, Felix oth Enthalten in Elsevier 625: Withdrawn 2013 AHJ Amsterdam [u.a.] (DE-627)ELV011791055 volume:188 year:2017 pages:11-17 extent:7 https://doi.org/10.1016/j.ahj.2017.02.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA AR 188 2017 11-17 7 045F 610 |
| language |
English |
| source |
Enthalten in 625: Withdrawn Amsterdam [u.a.] volume:188 year:2017 pages:11-17 extent:7 |
| sourceStr |
Enthalten in 625: Withdrawn Amsterdam [u.a.] volume:188 year:2017 pages:11-17 extent:7 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
625: Withdrawn |
| authorswithroles_txt_mv |
Kedhi, Elvin @@aut@@ Fabris, Enrico @@oth@@ van der Ent, Martin @@oth@@ Kennedy, Mark W. @@oth@@ Buszman, Pawel @@oth@@ von Birgelen, Clemens @@oth@@ Cook, Stéphane @@oth@@ Wedel, Hans @@oth@@ Zijlstra, Felix @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011791055 |
| dewey-sort |
3610 |
| id |
ELV030747783 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030747783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623210010.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ahj.2017.02.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017019000017.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030747783</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0002-8703(17)30053-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kedhi, Elvin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial”</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabris, Enrico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Ent, Martin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kennedy, Mark W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buszman, Pawel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Birgelen, Clemens</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cook, Stéphane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wedel, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zijlstra, Felix</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">625: Withdrawn</subfield><subfield code="d">2013</subfield><subfield code="d">AHJ</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011791055</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:188</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:11-17</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ahj.2017.02.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">188</subfield><subfield code="j">2017</subfield><subfield code="h">11-17</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Kedhi, Elvin |
| spellingShingle |
Kedhi, Elvin ddc 610 ddc 570 fid BIODIV A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” |
| authorStr |
Kedhi, Elvin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011791055 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” |
| topic |
ddc 610 ddc 570 fid BIODIV |
| topic_unstemmed |
ddc 610 ddc 570 fid BIODIV |
| topic_browse |
ddc 610 ddc 570 fid BIODIV |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e f ef d e m v dem demv m w k mw mwk p b pb b c v bc bcv s c sc h w hw f z fz |
| hierarchy_parent_title |
625: Withdrawn |
| hierarchy_parent_id |
ELV011791055 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
625: Withdrawn |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011791055 |
| title |
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” |
| ctrlnum |
(DE-627)ELV030747783 (ELSEVIER)S0002-8703(17)30053-4 |
| title_full |
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” |
| author_sort |
Kedhi, Elvin |
| journal |
625: Withdrawn |
| journalStr |
625: Withdrawn |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
11 |
| author_browse |
Kedhi, Elvin |
| container_volume |
188 |
| physical |
7 |
| class |
610 610 DE-600 610 VZ 570 VZ BIODIV DE-30 fid |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kedhi, Elvin |
| doi_str_mv |
10.1016/j.ahj.2017.02.018 |
| dewey-full |
610 570 |
| title_sort |
a prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in st-elevation myocardial infarction: rationale and design of the “dapt-stemi trial” |
| title_auth |
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” |
| abstract |
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. |
| abstractGer |
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. |
| abstract_unstemmed |
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
| title_short |
A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial” |
| url |
https://doi.org/10.1016/j.ahj.2017.02.018 |
| remote_bool |
true |
| author2 |
Fabris, Enrico van der Ent, Martin Kennedy, Mark W. Buszman, Pawel von Birgelen, Clemens Cook, Stéphane Wedel, Hans Zijlstra, Felix |
| author2Str |
Fabris, Enrico van der Ent, Martin Kennedy, Mark W. Buszman, Pawel von Birgelen, Clemens Cook, Stéphane Wedel, Hans Zijlstra, Felix |
| ppnlink |
ELV011791055 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ahj.2017.02.018 |
| up_date |
2024-07-06T18:23:17.534Z |
| _version_ |
1803855014169411584 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV030747783</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623210010.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ahj.2017.02.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2017019000017.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV030747783</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0002-8703(17)30053-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kedhi, Elvin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the “DAPT-STEMI trial”</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with second-generation drug eluting stents (DESs) is unclear. Because prolonged DAPT is associated with higher bleeding risk and health care costs, establishing optimal DAPT duration is of paramount importance. No other randomized controlled trials have evaluated the safety of shorter DAPT duration in ST-elevation myocardial infarction (STEMI) patients treated with second-generation DESs and latest P2Y12 platelet receptor inhibitors.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fabris, Enrico</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Ent, Martin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kennedy, Mark W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buszman, Pawel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">von Birgelen, Clemens</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cook, Stéphane</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wedel, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zijlstra, Felix</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="t">625: Withdrawn</subfield><subfield code="d">2013</subfield><subfield code="d">AHJ</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011791055</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:188</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:11-17</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ahj.2017.02.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">188</subfield><subfield code="j">2017</subfield><subfield code="h">11-17</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399884 |